Overview
- Description
Arthex Biotech (“The Company”) was founded in 2019 by Dr. Beatriz Llamusi and Dr. Ruben Artero as a spin-off of the University of Valencia where they have researched rare diseases, more specifically myotonic dystrophy type 1 (DM1 or Steinert’s disease). The Company has focused on the development of a first in class disease modifying strategy for the treatment of DM1. Their first product is an RNA-based therapy for DM1 that is currently in pre-clinical development. The Company aims to obtain validation of the proposed treatment (i.e. ATX-01, an orphan drug for intra-venous administration) and license it to large pharma companies for commercialization on large scale. Should their efforts be successful, ATX-01 could be first treatment for DM1 and open the doors for other potential diseases in which the regulation of miRNA plays a central role in the pathogenesis. The Company is currently raising its Series B equity round of min EUR 37m to start phase 1/2a clinical trial for its lead product ATX-01. The round is led by Columbus VC, a Spanish biotech experienced investor. Estimated closing in Q1 2023.
- Website
- Founded
2019
- Project
- Country
- Spain
- Theme
- Healthcare